We just signed the United States-Mexico-Canada Agreement. That agreement will extend the minimum data protection period for biologics from eight years to 10 years. So, we've just replicated that policy of extending patent protection to drug manufacturers. That means, of course, that U.S. drug companies will be able to protect their biologics from competition in Canada for a full decade.
As you just pointed out, Mr. Clark, given that according to the PMPRB seven of the 10 medicines—and I think you said eight—